Vir Biotechnology (VIR) Capital Expenditures (2018 - 2026)

Vir Biotechnology has disclosed Capital Expenditures across 9 years of filings, most recently posting $390000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $390000.0, down 76.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (down 49.09% YoY), and the FY2025 annual result was $4.8 million, down 33.82% from the prior year.
• Capital Expenditures came in at $390000.0 for Q1 2026 at Vir Biotechnology, up from $348000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $20.6 million in Q2 2022 to a low of $317000.0 in Q3 2025.
• The 5-year median for Capital Expenditures is $2.5 million (2025), against an average of $6.0 million.
• Across the five-year window, Capital Expenditures surged 4090.74% in 2022 and tumbled 92.96% in 2024, its largest moves.
• Vir Biotechnology's Capital Expenditures stood at $12.6 million in 2022, then plunged by 87.79% to $1.5 million in 2023, then climbed by 29.97% to $2.0 million in 2024, then tumbled by 82.56% to $348000.0 in 2025, then rose by 12.07% to $390000.0 in 2026.
• The last three Capital Expenditures figures came in at $390000.0 (Q1 2026), $348000.0 (Q4 2025), and $317000.0 (Q3 2025), per Business Quant data.